Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRAIN-4
2024-518192-61-00Phase 2Authorised
- Sponsor
- Netherlands Cancer Institute
- Start
- Nov 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of trastuzumab, pertuzumab and tucatinib in breast cancer, sponsored by Netherlands Cancer Institute. Primary endpoint: Incidence and severity of adverse events. Planned start Nov 2024; status: authorised.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2024-518192-61-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518192-61-00.